Johnson & Johnson Partner Contineum Slides as Depression Drug Fails
Contineum Therapeutics shares fall as Phase 2 MOONLIGHT-1 depression trial fails primary endpoint. Partner J&J reviews additional trial data.
Stocks · News reference
RBC Capital Maintains Outperform on Contineum Therapeutics, Raises Price Target to $23
RBC Capital analyst Brian Abrahams maintains Contineum Therapeutics (NASDAQ:CTNM) with a Outperform and raises the price target from $22 to $23.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Contineum Therapeutics shares are trading lower after Baird lowered its price target on the stock from $20 to $19.
Baird Maintains Outperform on Contineum Therapeutics, Lowers Price Target to $19
Baird analyst Joel Beatty maintains Contineum Therapeutics (NASDAQ:CTNM) with a Outperform and lowers the price target from $20 to $19.
Kestra Medical Technologies Posts Mixed Q1 Results, Joins Enova International, Dave and Buster's And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
Kestra Medical fell 8.6% after missing earnings estimates despite beating sales forecasts; several other stocks also declined premarket.